Hormonal
In Type 1 Diabetes (T1D), obesity and weight gain are increasingly common complications of intensive insulin therapy, contributing to insulin resistance and cardiovascular risk, but GLP-1 agonists and SGLT2 inhibitors show promise in mitigating weight gain.
If you have Type 1 Diabetes and are gaining weight despite insulin therapy, discuss adjunctive treatments like GLP-1 agonists or SGLT2 inhibitors with your doctor. These may help reduce insulin requirements and manage weight, addressing a common side effect of intensive insulin therapy.
Weight gain is also considered to be one of the side effects of intensive insulin treatment... Glucagon‐like peptide 1 (GLP‐1) receptor agonists... decreased insulin requirement and caused weight loss... Sodium‐glucose linked transporter 2 inhibitors... positively influence weight regulation.
Why this rating
Based on multiple studies and meta-analyses cited, though the paper notes ongoing investigation and mixed results for some drugs like metformin.
Source
Obesity and diabetes—Not only a simple link between two epidemics
Agata Chobot et al. · Diabetes/Metabolism Research and Reviews · 2018
DOI 10.1002/dmrr.3042
More from this paper
- Obesity is the primary environmental factor driving insulin resistance and the pathogenesis of Type 2 Diabetes (T2D) through mechanisms involving visceral fat distribution, ectopic lipid deposition, and gut microbiome dysbiosis.Strong
- Gut microbiome composition, specifically the ratio of Firmicutes to Bacteroidetes and the presence of Akkermansia muciniphila, influences obesity and diabetes risk through mechanisms involving short-chain fatty acid production, bile acid metabolism, and gut permeability.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →